Avalo Therapeutics, Inc. entered into a forbearance agreement with holders of a venture loan due to a default event. Additionally, the company has a non-binding letter of intent for the potential sale of AVTX-801, AVTX-802, and AVTX-803 series. As of July 20, 2023, the company had approximately $4.5 million in cash and cash equivalents.